Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the "Company" or "Blueberries"), a licensed Latin American producer of medical Cannabis and Cannabis-derived products, today announces that its wholly owned subsidiary Blueberries S.A.S. in Bogota, Colombia, obtained the registration of its agronomic operation area as a plant breeding unit and exporter of selected seeds.

This authorization by the Colombian Agricultural Institute (ICA), the authority responsible for the surveillance and control of the agricultural sector in Colombia, allows the company to consolidate its research and development activity around new cultivars with integral improvements from three points of view: increase performance and yield, extend cannabinoids and terpenes profiles, and simply agronomic management to improve the cost-effectiveness of the operation.

In addition, the registration as an exporter of selected seeds will allow the company to address emerging markets in Latin America and other regions, providing cuttings and seeds with the performance, adaptability, and consistency necessary to guarantee the operational standards of its strategic allies.

“The new capabilities of improving genetics and exporting seeds and cuttings are directly related with income generation and will help us to extend our sales streams internationally. We have been successful in selling our cultivars in Colombia, and more recently B2B services and extracts, so we are eager to start also commercializing our genetics in the global market. Indeed, there are some exercises with potential buyers in Argentina and Uruguay that we hope to announce soon”, said Jose Maria Forero, President of the operations in Latin America.

Facundo Garreton, Chief Executive Officer and Chairman of the Board, added that, “The access to superior genetics is a determinant factor to thrive in the industry, so we are very pleased that Blueberries has now the possibility to upgrade its genetic bank and to export seeds and clones of these strains to the international markets. It is also a great achievement that brings multiple possibilities and synergies with other companies of the Terraflos group, primarily with the plans that YVY is executing in Uruguay and Argentina”.

About Blueberries Medical Corp.

Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.

Additional information about the Company is available at www.blueberriesmed.com For more information, please contact:

Jose Forero, President, Latin American Operations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +57 310 345 8808

Guillermo Rodriguez, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +54 9 11 6015 2227

Cautionary Note Regarding Forward-Looking Information

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 and such other risk factors included in the management’s discussion and analysis of the Corporation for the year ended December 31, 2020, each filed on its issuer profile on SEDAR at www.sedar.com.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.